4D Molecular Therapeutics, Inc. (FDMT)

FDMT is a cash-rich late-stage gene-therapy developer with minimal debt and no explicit going-concern warning in recent SEC filings. Liquidity is strong (about $431M in cash/marketable securities at 6/30/2026 plus a new credit facility), but operating fundamentals remain weak with heavy losses and cash burn (TTM net margin near -195% and negative free-cash-flow yield). Because collaboration revenue is lumpy and product revenues are not yet established, valuation multiples based on sales should be treated cautiously; the story is primarily driven by Phase 3 and regulatory outcomes.

Dominant forward catalyst is the planned-but-unscheduled Phase 3 DME initiation (announced, Q3-2026 plan window, neutral — the quiet in-window tape offers no market reception to reward it); the 14-day media set is a post-Q2 lull of one routine conference PR and de minimis insider sales. Sentiment delta is a determinate cooling from a strongly bullish 30–90d baseline (+0.44) to a zero-scored recent fortnight (item-level, moderate confidence); Red-Flag Screen clean with no cap applied, but with no market-rewarded bullish element in-window the setup reads weak/forming.

Chart-quality read on 2026-09-08 would otherwise be ~4/5: price 14.63 above SMA20 14.45 / SMA50 12.57 / SMA200 10.13 and near EMA9 14.73, ADX 45.8 confirms a very strong uptrend off the August base, RSI 57.3 is neutral-positive, and volume is healthy. But the score is capped at 2 by the stale-feed gate: this is a partial run (cached=true) with no runDate in the envelope, so no trustworthy 'today' exists to anchor the chart or event windows (fail-closed per the run-date rule). Independently, the action is blocked by the qualitative override (qualitativeScore 2 < 3), so no trade plan is built regardless of the chart.